The Ozempic shortage is officially over—but that doesn’t mean compounded GLP-1s are going away. In this article, we explore why many patients still choose compounded semaglutide for affordability, flexibility, and convenience—even as brand-name options return to shelves.
For over a year, patients across the U.S. struggled to access Ozempic, the name-brand semaglutide injection used for type 2 diabetes and off-label weight loss. Shortages disrupted treatment plans and fueled the rise of telehealth and compounding alternatives.
But as of Spring 2025, the FDA has confirmed: the Ozempic shortage is officially over.
So… now what?
The FDA Says Supply Is Back—But Demand Is Still Sky High
Novo Nordisk has ramped up production, especially for Ozempic’s lower-dose pens, and the drug is now more reliably available in most pharmacies. However, access doesn’t automatically mean affordability or convenience.
Patients still face:
- Sticker shock for cash-pay prescriptions (often $900–$1,200/month)
- Long pharmacy waitlists in some areas
- Insurance headaches or denials for weight loss use
Can Compounding Pharmacies Still Sell Semaglutide?
Yes, they can—but only under specific conditions.
Under FDA regulations, compounding pharmacies can legally produce compounded semaglutide only if the commercially manufactured version (Ozempic, Wegovy) is listed on the FDA’s shortage list.
Here’s the nuance:
- As of May 2025, Ozempic (semaglutide for injection) is no longer on the list.
- However, Wegovy (semaglutide for weight loss) still is in limited supply in certain dose strengths.
- Many compounding pharmacies continue to offer compounded semaglutide for weight loss, citing that the branded version for this use case remains limited.
Additionally, some providers formulate semaglutide base or semaglutide sodium under state board guidelines and can continue selling as long as they do not misrepresent it as Ozempic.
Why Patients Still Choose Compounded Options
Even with brand-name supply restored, patients are sticking with compounders for good reasons:
- Weight loss-focused protocols: Many telehealth clinics offer support, coaching, and labs
- Lower cost: Often 50–75% cheaper than Ozempic
- Custom dosing: Blends with B12 or titration flexibility
- Faster shipping: No delays or pharmacy coordination
The Bottom Line
Yes, the Ozempic shortage is technically over—but compounded semaglutide continues to serve a vital role for patients seeking affordability, customization, and fast access through telehealth.
If you’re ready to start or stay on semaglutide, comparing your options is the smartest move. Branded meds may be back—but the convenience and price point of compounded GLP-1s are here to stay.
Looking for GLP-1 options that fit your lifestyle and budget? Click here to compare top providers.